Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $180.1100 (-0.57%) ($179.2500 - $182.9300) on Tue. Jul. 23, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.02% (three month average) | RSI | 55 | Latest Price | $180.1100(-0.57%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE advances 0.6% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) IBB(49%) IWO(46%) XBI(45%) IWC(43%) IWM(42%) | Factors Impacting SAGE price | SAGE will decline at least -1.01% in a week (0% probabilities). VIXM(-30%) VXX(-13%) TLT(-7%) UUP(-5%) IGOV(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.01% (StdDev 2.02%) | Hourly BBV | 0 () | Intraday Trend | -1.3% | | | |
|
Resistance Level | $182.33 | 5 Day Moving Average | $182.66(-1.4%) | 10 Day Moving Average | $184.64(-2.45%) | 20 Day Moving Average | $182.33(-1.22%) | To recent high | -5.2% | To recent low | 10.2% | Market Cap | $9.354b | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |